On April 21, 2026, Rapport Therapeutics reported positive results from the Phase 2a follow-up of RAP-219, showing an 80% median reduction in focal onset seizures during weeks 9-12 and a 90% median reduction during treatment periods. The drug's half-life increased from 14 days to approximately 22 days, demonstrating ongoing efficacy.